HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.

Georgios PapatheodoridisKostas MimidisSpilios ManolakopoulosNikolaos GatselisJohn GoulisAndreas KapataisEmanuel ManesisThemistoklis VasiliadisChristos TriantosDimitrios SamonakisVasilios SevastianosStelios KaratapanisIoannis ElefsiniotisMelanie DeutschTheodora MylopoulouMargarita PapatheodoridiHariklia KranidiotiPolyxeni AgorastouTheofani KaraoulaniAnastasia KyriazidouKonstantinos ZisimopoulosGeorge N Dalekos

Published in: Alimentary pharmacology & therapeutics (2022)

In mostly switched patients with renal and/or BMD disorders/risks, eGFR improved after 12-24 months of TAF treatment, especially in patients with baseline eGFR 30-60 ml/min. TAF may also improve low serum phosphate, BMD and ALT, whereas it maintains or induces virological suppression.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
human health
antiretroviral therapy
hepatitis b virus
hiv infected
bone mineral density
risk assessment
hiv infected patients
soft tissue
climate change
combination therapy
replacement therapy